ArticleCancer discovery2019
Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 101 citations in OpenAlex.
- Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.The Lancet. Haematology · 2020Trial
- Targeting Exportin-1 in Cancer: From Nuclear Export to Oncogenic Transcriptional Hubs.JMA journal · 2026Review
- SFPQ/S100A8 complex induces filaggrin deficiency via selective autophagy and JNK phosphorylation in atopic dermatitis.Cell communication and signaling : CCS · 2026Article
- Targeting the nuclear export receptor exportin-1 in acute myeloid leukaemia: From biology to clinical translation.Clinical and translational medicine · 2026Review
- Review
- XPO1 R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance.Cancer research · 2025Article
- Detection ofInternational journal of molecular sciences · 2025Article
- Exportin 1 (XPO1) Expression and Effectiveness of XPO1 Inhibitor Against Canine Lymphoma Cell Lines.Veterinary sciences · 2025Article
- CNS Involvement by North American-Adult T-cell Leukemia/Lymphoma Is Associated With Discrete Dissemination Patterns and Molecular Profiles, Involving XPO1 E571 and KLF2/PI3KCD in Selected Cases.JCO precision oncology · 2025Article
- Targeting the undruggable MYC in cancer: the rationale of using XPO1 inhibitors.Molecular biology reports · 2025Review
- MultiplexedbioRxiv : the preprint server for biology · 2025Article
- Targeting deubiquitinase USP7-mediated stabilization of XPO1 contributes to the anti-myeloma effects of selinexor.Journal of translational medicine · 2025Article
- Modulation of anti-tumour immunity by XPO1 inhibitors.Exploration of targeted anti-tumor therapy · 2025Review
- Prognostic and functional role of the nuclear export receptor 1 (XPO1) in gastrointestinal cancers: a potential novel target?Molecular biology reports · 2024Review
- Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia.Nature reviews. Clinical oncology · 2024Review
- Enhancing prediction of short linear protein motifs with Wregex 3.0.Computational and structural biotechnology journal · 2024Article
- Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition.Leukemia · 2024Article
- Exporting nuclear export inhibitors from hematologic to solid tumor malignancies.Clinical and translational discovery · 2024Article
- Exportin 1 governs the immunosuppressive functions of myeloid-derived suppressor cells in tumors through ERK1/2 nuclear export.Cellular & molecular immunology · 2024Article
- RHOF activation of AKT/β-catenin signaling pathway drives acute myeloid leukemia progression and chemotherapy resistance.iScience · 2024Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
27 authors at 3 institutions in 2 countries.
Justin TaylorHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4407-6325
Maria SendinoDepartment of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country, Barrio Sarriena s/n, Leioa, Spain.
Alexander N GorelickHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Alessandro PastoreHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-3621-4807
Matthew T ChangHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Alexander V PensonHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-2429-2370
Elena I GavrilaHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Connor StewartHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Ella M MelnikHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Florisela Herrejon ChavezMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-2238-0369
Lillian BitnerHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Akihide YoshimiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-0664-7281
Stanley Chun-Wei LeeHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Daichi InoueHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Bo LiuHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Xiao J ZhangHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Anthony R MatoLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Ahmet DoganDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Michael G KharasMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-1165-6991
Yuhong ChenBlood Research Institute, Blood Center of Wisconsin, Milwaukee, Wisconsin.
Demin WangBlood Research Institute, Blood Center of Wisconsin, Milwaukee, Wisconsin.
Rajesh K SoniMicrochemistry and Proteomics Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
Ronald C HendricksonMicrochemistry and Proteomics Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
Gorka PrietoDepartment of Communications Engineering, University of the Basque Country (UPV/EHU), Bilbao, Spain.ORCID 0000-0002-6433-8452
Jose A RodriguezDepartment of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country, Barrio Sarriena s/n, Leioa, Spain.
Barry S TaylorHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4407-6325
Omar Abdel-WahabHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. abdelwao@mskcc.org.
Memorial Sloan Kettering Cancer Center · USUniversity of the Basque Country · ESVersiti Blood Center of Wisconsin · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MMSKCC Pilot Center for Precision Disease ModelingU54OD020355 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W., SOLIT, DAVID B. · 2015 to 2019
$9.9MGenetic and molecular basis for SRSF2 mutations in myelodysplasiaR01HL128239 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Omar Abdel-Wahab, Robert K Bradley · 2015 to 2026
$8.0MB cell responses in heparin-induced thrombocytopeniaR01HL130724 · NHLBI · VERSITI WISCONSIN, INC. · PI WANG, DEMIN · 2017 to 2024
$4.8MPLC?s in B cell biology and autoimmunityR01AI079087 · NIAID · VERSITI WISCONSIN, INC. · PI WANG, DEMIN · 2008 to 2018
$4.4MOrigins of BRAF-mutant hematologic malignancies and their therapeutic resistanceR01CA201247 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR, PARK, CHRISTOPHER Y · 2016 to 2020
$2.7MUnderstanding Long Tail Driver Mutations in CancerR01CA204749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCHULTZ, NIKOLAUS · 2017 to 2021
$2.0MTargeting AKT-Mutant Human CancersR01CA207244 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SOLIT, DAVID B. · 2016 to 2020
$2.0MDefining the Biological and Mechanistic Implications of XPO1 Mutations in Hematologic MalignanciesK08CA230319 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI TAYLOR, JUSTIN · 2018 to 2023
$1.2MDefining Novel Genetic Dependencies in Spliceosome Mutant LeukemiaK99CA218896 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEE, STANLEY CHUN-WEI · 2017 to 2018
$297kNCI NIH HHS K08 CA230319NCI NIH HHS K99 CA218896NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA201247NCI NIH HHS R01 CA204749NCI NIH HHS R01 CA207244NHLBI NIH HHS R01 HL128239NHLBI NIH HHS R01 HL130724NIAID NIH HHS R01 AI079087NIH HHS U54 OD020355
Abstract
Altered expression of XPO1, the main nuclear export receptor in eukaryotic cells, has been observed in cancer, and XPO1 has been a focus of anticancer drug development. However, mechanistic evidence for cancer-specific alterations in XPO1 function is lacking. Here, genomic analysis of 42,793 cancers identified recurrent and previously unrecognized mutational hotspots in
Indexed as
Cell Transformation, NeoplasticNuclear Export SignalsActive Transport, Cell NucleusAnimalsCell ProliferationDisease Models, AnimalExportin 1 ProteinGene ExpressionGenes, bcl-2Genes, mycHumansKaryopherinsLeukemia, B-CellMiceMutationOrgan SpecificityExportin 1 ProteinKaryopherinsNuclear Export SignalsReceptors, Cytoplasmic and Nuclear
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.